UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CLEARCORRECT OPERATING LLC,
Petitioner,

v.

ALIGN TECHNOLOGY, INC.,
Patent Owner.

IPR2025-00818
IPR2025-00819
IPR2025-00820
IPR2025-00821
Patent Nos. 10,973,613,
11,154,384,
11,648,090,
11,648,091

DECLARATION OF NAGA KUSIMA

DECLARATION OF NAGA KUSIMA

I, Naga Kusima, declare and state as follows:

1. I am the Vice President of Corporate Financial Planning & Analysis for Align Technology, Inc. ("Align"). I began my employment with Align in 2009 as Senior Finance and Business Development Manager. In my capacity as Vice President of Corporate Financial Planning & Analysis, I am knowledgeable about Align's finances in the marketplace and revenue. I make this declaration based on my personal knowledge of the facts and on a review of the supporting data records for Align, unless I otherwise indicate that I have stated the matters on information and belief.

2. Align is a global medical device company primarily engaged in the design, manufacture, and marketing of Invisalign® Clear Aligners for the treatment of misaligned teeth and malocclusions (misaligned bite) by dentists, Vivera™ retainers for retention, iTero™ intraoral scanners and services for dentistry, and exocad™ computer-aided design and computer-aided manufacturing ("CAD/CAM") software for dental laboratories and dental practitioners.

3. I understand that Straumann is challenging four of Align's patents related to multilayer materials, specifically: U.S. Pat. Nos. 10,973,613; 11,154,384; 11,648,090; 11,648,091. I have been asked to provide

information about Align's financial success since switching to multilayer material.

4. Align commercially introduced its multilayer material, SmartTrack, in 2013.

Q1 FY2013 Financial Highlights

	Total	Invisalign Clear Aligners		Scanner & CAD/CAM
	$153.6M	$141.6M	98,175cases	$12.0M
QoQ	+7.5%	+6.6%	+8.5%	+20.3%
YoY	+13.7%	+14.8%	+15.1%	+2.2%

- Q1 was a solid quarter across the board. We've started the year with better than expected revenue and earnings driven primarily by record Invisalign case volume.
- Strong Invisalign case shipments in North America, especially among Orthodontists, reflect stable patient traffic in our customers' offices, as well as continued sales and marketing activity to encourage doctor engagement.
- During the quarter we launched SmartTrack, our next generation aligner material. We have received consistently positive feedback from our customers and their patients as they move beyond initial usage. We're excited about the potential for SmartTrack to help build even greater clinical confidence so our doctors will utilize Invisalign more often and on more complex cases.

5 Align Technology, Inc. All rights reserved

invisalign iTero iOC OrthoCAD

EX2030 (2013 Q1 Quarterly Results slides), 5 (highlighted). Before that time, I understand that Align used a single layer material called EX-30 and before that, a material called PC-30.

5. Align first released its Invisalign System in 1999. By 2012 – the year immediately before manufacturing aligners with SmartTrack, Align had only treated 2 million patients since its formation. EX2031 (2012 Q4 Quarterly

Results slides), 14. Since switching to SmartTrack, Align has treated over 10 times that amount, treating over 20 million additional patients.

EX2032 (2025 Q4 Quarterly Results slides), 5. In 2025 alone, Align treated over 2 million patients globally. *Id.*

6. As the number of patients treated by Align exploded post-SmartTrack, so did Align's revenue. Align's revenue has gone from just over $500 million in 2012—the year immediately preceding the launch of SmartTrack—to $3.2

billion annually on clear aligners alone in 2025.[1] EX2031 (2012 Q4 Quarterly Results slides), 32; EX2032 (2025 Q4 Quarterly Results slides), 11. This astronomical growth is tied, in part, to Align's use of SmartTrack material.

7. In signing this declaration, I understand that the declaration will be filed as evidence in a contested case before the Patent Trial and Appeal Board of the United States Patent and Trademark Office. I acknowledge that I may be subject to cross-examination in this case and that cross-examination will take place within the United States. If cross-examination is required of me, I will appear for cross-examination within the United States during the time allotted for cross-examination.

8. I declare that all statements made herein of my knowledge are true, and that all statements made on information and belief are believed to be true, and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or

---

[1] These annual revenue figures are as reported in Align's Quarterly Financial Results slides for Q4 for the respective years. Align's Quarterly Financial Results slides are publicly available for download at the following web address: https://investor.aligntech.com/financial-information/quarterly-results. While the currently available slides go back to 2013, the 2012 slides I cite here (EX2031), which come from Align's records, are also archived at the following web address: .

imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Dated: February 20, 2026 By: _____
Naga Kusima